|
WEDNESDAY, Sept. 15 (HealthDayNews) -- A drug being tested as a
cancer treatment may also reduce the kidney disease that can be
caused by lupus, according to a Wake Forest University Baptist Medical
Center study.
Researchers found the drug SAHA (suberoylanilide hydroxamic acid)
inhibited the onset of lupus-related kidney disease in mice. The
study appears in the Sept. 15 issue of the Journal of Immunology.
In addition to preventing kidney diseases in the mice, the drug
reduced the size of the spleen and decreased production of certain
T-cells that play an important role in lupus. The drug also decreased
excess protein in the urine of the mice.
The mice that received SAHA showed no adverse effects.
This study received funding from Aton Pharma Inc., which holds
the license for SAHA.
The researchers plan to start a Phase I clinical trial of SAHA
in lupus patients next year to assess the drug's safety.
|
Message
Boards
